Skip to main content

News

| Press release
Laboratory group Laboratoires Réunis capitalizes Genetic Information Management software suite for complex laboratory reports

Laboratoires Réunis group is a further client for bio.logis Genetic Information Management GmbH’s “Genetic Information Management Suite (GIMS)”, specially developed for genetic diagnostics. Usage will initially focus on establishing the creation of highly complex diagnostic reports with a maximum degree of efficiency and automation.

read more >
| Press release
Laboratory group Laboratoires Réunis capitalizes Genetic Information Management software suite for complex laboratory reports

One of the largest private laboratories in Luxembourg uses the bio.logis Genetic Information Management Suite (GIMS) to automate the creation of extensive diagnostic reports

Laboratoires Réunis group is a further client for bio.logis Genetic Information Management GmbH’s “Genetic Information Management Suite (GIMS)”, specially developed for genetic diagnostics. Usage will initially focus on establishing the creation of highly complex diagnostic reports with a maximum degree of efficiency and automation. 

With more than 50 blood sampling locations, a centralized laboratory in Junglinster, Luxembourg, as well as laboratory sites in Trier, Germany, and Fléron, Belgium, Laboratoires Réunis is one of the largest private laboratories in Luxembourg and considered to be a national pioneer for molecular diagnostics and personalized medicine. Apart from a broad spectrum of analyses in areas such as clinical chemistry or immunology, the Laboratoires Réunis group also offers a number of genetic analyses, a field in which it wants to expand further in future. In order to meet the challenges of efficiently producing high-quality clinical reports during these complex analyses, the lab’s scientists now use bio.logis GIM’s IT solution, specifically designed for this area of application. 

The starting point is the introduction of the software suite’s “Diagnostic Report Module (DRM)” to largely automate the creation of diagnostic reports on the basis of genetic analysis results. Using a centralized content management system for medical content ensures that the reports are also standardized and always up to date. DRM makes the reporting process highly efficient and improves its scalability. In addition, there are plans to successively introduce more Genetic Information Management Suite modules to further optimize existing processes. Both parties are also working on establishing individual functionalities of the Diagnostic Report Module so that other diagnostic fields also benefit from enhanced efficiency. 

“The Diagnostic Report Module is an enormous help for our scientific experts, who create complex reports on a daily basis,” says Dr Martin Schöndorf, Director Business Unit at Laboratoires Réunis, praising the collaboration with the men and women at bio.logis. “There is only one word to describe the support we received during the roll-out as well as the willingness and ability to adapt the solutions to our requirements and existing infrastructure—excellent.” Enrico Just, Managing Director, bio.logis GIM, adds: “We are very happy to have found a further renowned customer and reliable partner in Laboratoires Réunis, who also supports the improvement and evolution of our solutions with its own expertise and ideas.” 

About bio.logis Genetic Information Management GmbH
bio.logis Genetic Information Management GmbH translates genetic data into medically leverageable information and makes it available to physicians and patients. To that end, it has developed a special “Genetic Information Management Suite (GIMS)” IT solution which, in the process chain required for genetic diagnostics, focuses on the "last mile” from physician to patient by merging raw genetic data with clinically leverageable knowledge for prompt application. GIMS supports physicians both in laboratories for automatically generating such expert content, and in hospitals with specific clinical suggestions. The physician reports and recommended action generated by GIMS is delivered straight to the point of care via laboratory and physician information systems as well as electronic health records. For more information about our company and our products, please visit https://www.biologis.com/.

Press relations:

Dr. Maike Post
bio.logis Genetic Information Management GmbH
Altenhöferallee 3
D-60438 Frankfurt am Main
Phone: +49 (0) 69 3487391 31
maike.post@biologis.com

Dr. Carolin Nowak
bio.logis Genetic Information Management GmbH
Altenhöferallee 3
D-60438 Frankfurt am Main
Phone: +49 (0) 69 3487391 44
carolin.nowak@biologis.com

Manuela Rost-Hein
Ketchum Pleon
c/o Torstrasse 140
D-10119 Berlin
Phone: +49 (0) 30 400 54 752
manuela.rost-hein@ketchumpleon.com

| Article
bio.logis GIM launches first version of an iOS mobile app for personalized drug therapy

The “pharma.sensor” developed by bio.logis Genetic Information Management GmbH (bio.logis GIM) is a new mobile app for pharmacogenomics. The app shows whether certain DNA variants have to be considered for the safe efficacy of a drug. With this knowledge, the app user can identify if genotyping is useful prior of starting a drug therapy. The drug check is performed by simply entering a drug name or scanning the barcode on the packaging. The app is available in German and English via the Apple app store and is free of charge.

read more >
| Article
bio.logis GIM launches first version of an iOS mobile app for personalized drug therapy

Decisions for drugs and active ingredients depending on genetic variants / Individual drug therapies are supported

The “pharma.sensor” developed by bio.logis Genetic Information Management GmbH (bio.logis GIM) is a new mobile app for pharmacogenomics. The app shows whether certain DNA variants have to be considered for the safe efficacy of a drug. With this knowledge, the app user can identify if genotyping is useful prior of starting a drug therapy. The drug check is performed by simply entering a drug name or scanning the barcode on the packaging. The app is available in German and English via the Apple app store and is free of charge.

The DNA of every person is unique, nobody completely equals another person. This also affects the metabolism of drugs. Back in the sixties, pharmacologists found out that various human genetic variants lead to different efficacy of certain drugs. Especially antibiotics, chemotherapeutics, HIV therapeutics, oral antidiabetics, psychotropic drugs or analgesics are metabolized differently. If genetic variants are taken into consideration, recommendations for adjusting the dose or prescribing an alternative therapy can be given.

A huge amount of information about genetic variants being important for many drugs couldn’t be used in the clinical practice so far because no supporting tools have been available. Therefore, bio.logis GIM developed the “pharma.sensor” app to check whether there exists relevant DNA information for the efficacy or rather tolerance of different drugs, respectively. If so, a genetic test can be considered.

With just a few clicks, such a genetic test can be ordered directly via the “pharma.sensor” app. For this purpose, the app links to the services of the bio.logis Center for Human Genetics, a specialist for genetic analyses. Other partners will be included in the future as well.

 

The “pharma.sensor” app is available via the Apple App Store and can be downloaded free of charge.
A version for Android will also be available soon.

| Article
ESHG 2017: Post-Event News

bio.logis Genetic Information Management GmbH was present at the European Human Genetics Conference from May 27 to 30, 2017.

read more >
| Article
ESHG 2017: Post-Event News

bio.logis Genetic Information Management (GIM) was present at the European Human Genetics Conference from May 27 to 30, 2017. Celebrating its 50th anniversary, the annual conference took place in Copenhagen where it was held for the first time in 1967. With more than 3,500 attendees and over 150 exhibitors this international meeting is a forum for everybody working in human and medical genetics: researchers, clinicians and companies delivering diagnostic services. At the ESHG 2017 conference the latest findings in the field of basic and applied human genetics were presented and in oral presentations, workshops and educational sessions, professionals from all over the world were able to share their knowledge and advancements.

At the bio.logis booth our team appreciated to present our Genetic Information Management Suite (GIMS) and to connect with stakeholders and potential customers. In many live demos visitors explored the Diagnostic Report Module (DRM) and learned how our modules can essentially support and drive the adoption of human genetic diagnostics into clinical practice.

Thanks to the organization team and we are already looking forward to next year in Milan!

booth of bio.logis GIM at the ESHG 2017
Venue of ESHG 2017: Bella Center in Copenhagen
| Press release
bio.logis launches new add-on for Diagnostic Report Module

The "Genetic Information Management Suite", or GIMS in short, supports laboratories in efficiently translating laboratory findings into clinically leverageable and easily understood information for physicians and patients. At the heart of the software suite is the "Diagnostic Report Module", or DRM, enabling up to 95% of cost and time savings when creating diagnostic reports. With the introduction of the "Report Layout Engine" (RLE), bio.logis is expanding GIMS by another key building block to respond yet more flexibly to the requests and needs of diagnostic laboratories.

read more >
| Press release
bio.logis launches new add-on for Diagnostic Report Module

bio.logis Genetic Information Management GmbH’s "Report Layout Engine" enables direct conversion of structured report content into mailable diagnostic reports

The "Genetic Information Management Suite", or GIMS in short, supports laboratories in efficiently translating laboratory findings into clinically leverageable and easily understood information for physicians and patients. At the heart of the software suite is the "Diagnostic Report Module", or DRM, enabling up to 95% of cost and time savings when creating diagnostic reports. With the introduction of the "Report Layout Engine" (RLE), bio.logis is expanding GIMS by another key building block to respond yet more flexibly to the requests and needs of diagnostic laboratories.

DRM supports the production of human genetic diagnostic reports by efficiently managing text and image content as well as automatically allocating content to laboratory findings. Every laboratory working with DRM receives its own, secure DRM instance, hosted in Germany by fully certified, dedicated Deutsche Telekom data centers. DRM contains a fully functional CMS (Content Management System) for structured creation and efficient management of all the content required for diagnostic reports. Human genetics reports are automatically compiled on the basis of laboratory result data and only require medical validation, meaning that the production of these reports can be largely automated.

By default, these reports are sent as structured data to the client's LIMS (Laboratory Information Management System) where they are linked to the patient’s data and transferred to the lab’s diagnostic report layout. In case the client’s LIMS has no or only insufficient functions for creating final documents, GIMS now has a new component - the "Report Layout Engine". It enables transferring DRM-created report content into final documents of common output formats. Converting structured data into final diagnostic reports can be applied to any type of content such as text, lab values, diagrams, tables, references, etc. For the output, the engine uses templates created by the lab itself inside the system and centrally managed using clear workflows. This ensures that labs have full control of layout, design, and branding so this information is always up to date on all the documents.

“When talking to our clients it became clear that not all Laboratory Information Management Systems provide the necessary functionalities for creating document or that users were not happy with the existing solutions. So we addressed our clients’ needs for a solution by developing our Report Layout Engine. It is available now as a DRM add-on for labs, helping us to respond yet more flexibly to our clients’ existing IT infrastructure,” says Dr. Maike Post, Chief Marketing Officer at bio.logis Genetic Information Management GmbH. For the future, bio.logis want to leverage GIMS’ benefits also for other diagnostic laboratory areas. “Our Report Layout Engine is a first step into that direction,” adds Chief Technology Officer, Markus Kalkbrenner. “Over the course of the past few months, clients and prospects indicated that they would like to use this solution for creating reports in other fields, too. Therefore, we are also working on a standalone version of our Report Layout Engine.”

About bio.logis Genetic Information Management GmbH
bio.logis Genetic Information Management GmbH translates genetic data into medically leverageable information and makes it available to physicians and patients. To that end, it has developed a special "Genetic Information Management System (GIMS)" IT solution which, in the process chain required for genetic diagnostics, focuses on the "last mile" from physician to patient by merging raw genetic data with clinically leverageable knowledge for prompt application. GIMS supports physicians both in laboratories for automatically generating such expert content, and in hospitals with specific clinical suggestions. The physician reports and recommended action generated by GIMS is delivered straight to the point of care via laboratory and physician information systems as well as electronic health records. For more information about our company and our products, please visit https://www.biologis.com/.

Press relations:

Dr. Maike Post
bio.logis Genetic Information Management GmbH
Altenhöferallee 3
60438 Frankfurt am Main
Telefon:   +49 (0) 69-530 8437-33
Fax:        +49 (0) 69-530 8437-11
Mobil:     +49 (0) 175-2245156
maike.post@bio.logis.com

Manuela Rost-Hein
Ketchum Pleon
c/o Torstrasse 140
10119 Berlin
Telefon: +49 (0) 30-400 54 752
manuela.rost-hein@ketchumpleon.com

| Press release
Successful launch of bio.logis GIMS in “U-PGx” EU project

This EU-funded project is part of the Horizon 2020 program “Ubiquitous Pharmacogenomics“ (U-PGx) and aimed at driving the implementation of pharmacogenetics in diagnostic and clinical practice. The objective is to treat patients with medication and doses that are ideally suited to their personal genetic make-up. As part of this project, bio.logis Genetic Information Management GmbH, based in Frankfurt, will make its GIMS Genetic Information Management Suite available, which was specifically developed for genetic diagnostics. GIMS has now been implemented in the first three of a total of seven European university hospitals, enabling maximized efficiency in creating customized reports with easily understood pharmacogenetic recommendations for physicians and patients.

read more >
| Press release
Successful launch of bio.logis GIMS in “U-PGx” EU project

The U-PGx EU project for supporting the application of pharmacogenetics in clinical practice / bio.logis’ Genetic Information Management Suite (GIMS) commissioned by three European university hospitals

This EU-funded project is part of the Horizon 2020 program “Ubiquitous Pharmacogenomics“ (U-PGx) and aimed at driving the implementation of pharmacogenetics in diagnostic and clinical practice. The objective is to treat patients with medication and doses that are ideally suited to their personal genetic make-up. As part of this project, bio.logis Genetic Information Management GmbH, based in Frankfurt, will make its GIMS Genetic Information Management Suite available, which was specifically developed for genetic diagnostics. GIMS has now been implemented in the first three of a total of seven European university hospitals, enabling maximized efficiency in creating customized reports with easily understood pharmacogenetic recommendations for physicians and patients.

As part of the U-PGx project, seven notable European university hospitals will, over the course of the next five years, analyze the genetic make-up of over 8,000 patients taking one of 84 selected drugs. This is based on the fact that there is a known relationship between the individual effect of these drugs and the patient’s genetic make-up (pharmacogenetics). In addition, specific treatment and proposed dosage recommendations can be displayed depending on the analysis results. The recommended action and proposed dosage recommendations for these drugs are provided by the internationally renowned KNMP (the Royal Dutch Pharmacists Association). In the last few months, these recommendations have been translated into their local languages by the participating university hospitals using GIMS. With the project now having started officially, the university hospitals in Granada, Patras and Ljubljana are in the process of recruiting their first patients. The other hospitals in Leiden, Vienna, Liverpool and Aviano are supposed to follow next year.

The IT solutions developed by bio.logis support genetic laboratories with translating analysis results into leverageable clinical information and recommended action. GIMS enables the efficient automated production of diagnostic reports as well as the digital delivery of results and information to physicians and patients. The software suite’s “Diagnostic Report Module” used in U-PGx has the CE mark to identify it as a class I medical product. Using GIMS in this EU project enables participating hospitals to automatically create standardized diagnostic reports based on state-of-the-art scientific knowledge and the collated laboratory findings. The reports are created in seconds and can be delivered in the local language. The reports can be accessed online via a secure Web portal regardless of the physician’s or patient’s location. “Introducing our GIMS solutions within this EU project enabled us to show that high-quality standardization and leveraging of continuously growing data volumes and insights in medicine is only possible with the help of IT. It is our vision to support and facilitate the physician’s daily job with our developments to contribute to customized and efficient patient care,” said Enrico Just, Managing Director, who will introduce GIMS to the wider public in Vienna on May 11 at the 2nd U-PGx Annual Consortium Meeting.
For more information on the "Ubiquitous Pharmacogenomics” EU project, please visit http://upgx.eu/

About bio.logis Genetic Information Management GmbH
bio.logis Genetic Information Management GmbH translates genetic data into medically leverageable information and makes it available to physicians and patients. To that end, it has developed a special "Genetic Information Management System (GIMS)" IT solution which, in the process chain required for genetic diagnostics, focuses on the "last mile" from physician to patient by merging raw genetic data with clinically leverageable knowledge for prompt application. GIMS supports physicians both in laboratories for automatically generating such expert content, and in hospitals with specific clinical suggestions. The physician reports and recommended action generated by GIMS is delivered straight to the point of care via laboratory and physician information systems as well as electronic health records. For more information about our company and our products, please visit https://www.biologis.de/.

About U-PGx (Ubiquitous Pharmacogenomics)
This project has received funding from the European Union’s Horizon 2020 research and innovation program under grant agreement No 668353.

Press Relations:

Dr. Maike Post
bio.logis Genetic Information Management GmbH
Altenhöferallee 3
D-60438 Frankfurt am Main
Phone:   +49 (0) 69 530 8437 33
Fax:        +49 (0) 69 530 8437 11
Cell:     +49 (0) 175 2245156
maike.post@bio.logis.com

Manuela Rost-Hein
Ketchum Pleon
c/o Torstrasse 140
D-10119 Berlin
Phone: +49 (0) 30 400 54 752
manuela.rost-hein@ketchumpleon.com

| Article
bio.logis as contributer at the Drupal Camp, Frankfurt

Last weekend bio.logis contributed to a successful Drupal Camp 2017 in Frankfurt with 3 sessions, 1 informal discussion group (“Birds of a feather” session, BoF) and a Gold Sponsorship.

read more >
| Article
bio.logis as contributer at the Drupal Camp, Frankfurt

Last weekend bio.logis contributed to a successful Drupal Camp 2017 in Frankfurt with 3 sessions, 1 informal discussion group (“Birds of a feather” session, BoF) and a Gold Sponsorship.

The open source CMS Drupal is used for different Health IT-solutions by bio.logis GIM. That’s why for many years the bio.logis GIM-team is not only engaged in various events of the Drupal community but also supports the further development of Drupal itself and its numerous extension modules.

Get some pictures of the camp here: 

Drupal Camp 2017 in Frankfurt
| Press release
bio.logis receives CE mark for its Diagnostic Report Module for efficient production of diagnostic reports in laboratories

bio.logis Genetic Information Management GmbH has achieved the next decisive level for establishing its Genetic Information Management Suite (GIMS) as a quality product for genetic diagnostics: The software suite’s currently most important component—the Diagnostic Report Module (DRM)—has been certified by the Federal Association for Internet Medicine (BiM) as an “Internet medicine quality product” and has also received the CE mark as a Medical Device Class I (according to EEC 93/42, EC 2007/47).

read more >
| Press release
bio.logis receives CE mark for its Diagnostic Report Module for efficient production of diagnostic reports in laboratories

Certification of the Diagnostic Report Module, part of the Genetic Information Management Suite developed by bio.logis, as an “Internet medicine quality product” and a "Medical Device Class I" according to European standards

bio.logis Genetic Information Management GmbH has achieved the next decisive level for establishing its Genetic Information Management Suite (GIMS) as a quality product for genetic diagnostics: The software suite’s currently most important component—the Diagnostic Report Module (DRM)—has been certified by the Federal Association for Internet Medicine (BiM) as an “Internet medicine quality product” and has also received the CE mark as a Medical Device Class I (according to EEC 93/42, EC 2007/47).

GIMS, a dedicated software suite, supports laboratories with several modules in interpreting genetic data and providing clinically relevant information for physicians and patients. The Diagnostic Report Module (DRM) is used to efficiently generate diagnostic reports—a process which is still highly manual, complex, fragmented, and therefore very time-consuming.  The DRM integrates with the laboratory’s IT infrastructure via standard interfaces to receive anonymized findings that are relevant for the diagnosis. The module contains a fully functional CMS (Content Management System) for the management of content and centralized generation of diagnostic reports. Based on the imported data, a Report Engine then compiles the right content into a diagnostic report. The main advantage for laboratories is the fact that they will be able to handle complex clinical data structures and save significant time and costs by automating previously manual process steps. With all the necessary content being created and managed in a centralized instance, DRM also helps laboratories to design consistent high-quality diagnostic reports. Currently, DRM is being implemented in seven selected university hospitals in seven European countries as part of the Horizon 2020 Initiative’s Ubiquitous Pharmacogenomics EU project.

With the CE mark for its DRM, bio.logis emphasizes standardized medical quality. The seal not only certifies the product’s quality according to valid European guidelines but also confirms its fitness to be used for the intended medical purpose. With this tool, bio.logis offers all users of the Genetic Information Management Suite more efficient processes as well as legal certainty in the application of this high-quality product for genetic diagnostics.

About bio.logis Genetic Information Management GmbH
bio.logis Genetic Information Management GmbH supports laboratories in translating genetic data into medically leverageable information and making it available to physicians and patients. To that end, it has developed a special "Genetic Information Management Suite (GIMS)" which, in the process chain required for genetic diagnostics, focuses on the "last mile" from physician to patient by merging raw genetic data with clinically leverageable knowledge for prompt application. GIMS supports physicians both in laboratories for automatically generating such expert content, and in hospitals or surgeries with specific clinical treatment proposals. The physician reports and recommended action generated by GIMS is delivered straight to the point of care via laboratory and physician information systems as well as electronic health records.

Press Relations:

Dr. Maike Post
bio.logis Genetic Information Management GmbH
Altenhöferallee 3
60438 Frankfurt am Main
Telefon:+49 (0) 69-530 8437-33
Fax:      +49 (0) 69-530 8437-11
maike.post@bio.logis.de

Manuela Rost-Hein
Ketchum Pleon
c/o Torstrasse 140
10119 Berlin
Telefon: +49 (0) 30-400 54 752
manuela.rost-hein@ketchumpleon.com

| Press release
bio.logis receives €2.4m for implementing pharmacogenomic systems in Europe

Pharmacogenomics deals with the questions of whether an individual's genetic make-up affects the efficacy of drugs and/or how to leverage genetic information to optimize drug therapies. The buzz word is: Personalized medicine. The EU is now making a total of €15m available for driving the practical implementation of genetic knowledge to improve therapeutic decision-making. This supports the European U-PGx (Ubiquitous Pharmacogenomics) consortium. bio.logis Genetic Information Management GmbH, based in Frankfurt am Main, Germany, is a member of this consortium and has been concentrating on the issue for years, with a specific focus on developing genetic information management systems. bio.logis will receive €2.4m from these funds to implement its Genetic Information Management Suite (GIMS) along with technologies for genotyping in selected hospitals across Europe (the Netherlands, UK, Austria, Greece, Italy, Spain, Slovenia) for application in day-to-day clinical operations.

read more >
| Press release
bio.logis receives €2.4m for implementing pharmacogenomic systems in Europe

U-PGx EU project for supporting the application of pharmacogenomics in clinical practice / bio.logis responsible for implementing genetic information management systems at selected hospitals

Pharmacogenomics deals with the questions of whether an individual's genetic make-up affects the efficacy of drugs and/or how to leverage genetic information to optimize drug therapies. The buzz word is: Personalized medicine. The EU is now making a total of €15m available for driving the practical implementation of genetic knowledge to improve therapeutic decision-making. This supports the European U-PGx (Ubiquitous Pharmacogenomics) consortium. bio.logis Genetic Information Management GmbH, based in Frankfurt am Main, Germany, is a member of this consortium and has been concentrating on the issue for years, with a specific focus on developing genetic information management systems. bio.logis will receive €2.4m from these funds to implement its Genetic Information Management Suite (GIMS) along with technologies for genotyping in selected hospitals across Europe (the Netherlands, UK, Austria, Greece, Italy, Spain, Slovenia) for application in day-to-day clinical operations.

"In the long-term, personalized medicine will become a standard option for medical treatment," says Professor Henk-Jan Guchelaar, Head of the Department of Clinical Pharmacy and Toxicology at the Leiden University Medical Center in the Netherlands, and coordinator of the U-PGx project. The consortium's and the EU's objective is to optimize therapies and treatments based on genetic insight and to make them available to all European citizens. 
Apart from basic research and developing specific therapies, a decisive aspect is the development and application of relevant genotyping technologies. In addition, IT systems are required for processing genetic information to leverage them for medical decision-making. This latter discipline is what bio.logis Genetic Information Management (GIM), a bio.logis division, is specializing in. Its GIMS is the leading solution in Europe, and the division is now receiving funds from the EU budget for integrating its system into the clinical workflows of selected European hospitals.
"Implementing our Genetic Information Management solution in seven European hospitals that are leaders in pharmacogenomics brings us a huge step closer to our goal, i.e., providing genetic information for medical decision-making on as wide a basis and for as many patients as possible," says Prof. Dr. med. Daniela Steinberger, Human Geneticist, Medical Director and Managing Director of bio.logis Genetic Information Management GmbH.

bio.logis is also participating in another EU project which, under Dutch leadership, is developing concepts for a "Genetics Clinic of the Future (GCOF)." This project also aims at driving the clinical implementation of genetic information.

About bio.logis Genetic Information Management GmbH
bio.logis Genetic Information Management GmbH translates genetic data into medically leverageable information and makes it available to physicians and patients. To that end, it has developed a special "Genetic Information Management Suite (GIMS)" IT solution which, in the process chain required for genetic diagnostics, focuses on the "last mile" to physicians and patients by merging raw genetic data with clinically leverageable knowledge for prompt application. GIMS supports physicians both in laboratories for automatically generating such expert content, and in hospitals with specific clinical suggestions. The diagnostic reports and medical recommendations generated with GIMS are delivered straight to the point of care via laboratory and physician information systems as well as electronic health records.

About U-PGx (Ubiquitous Pharmacogenomics)
This project has received funding from the European Union’s Horizon 2020 research and innovation program under grant agreement No 668353.

Press Relations:

Dr. Maike Post
bio.logis Genetic Information Management GmbH
Altenhöferallee 3
D-60438 Frankfurt am Main
Phone:   +49 (0) 69 530 8437 33
Fax:        +49 (0) 69 530 8437 11
maike.post@bio.logis.de

Prof. Dr. med. Daniela Steinberger
bio.logis Genetic Information Management GmbH
Altenhöferallee 3
D-60438 Frankfurt am Main
Phone:   +49 (0) 69 530 8437 0
Fax:        +49 (0) 69 530 8437 11
daniela.steinberger@bio.logis.de

Manuela Rost-Hein
Ketchum Pleon
c/o Torstrasse 140
D-10119 Berlin
Phone: +49 (0) 30 400 54 752
manuela.rost-hein@ketchumpleon.com